Canakinumab shows promising efficacy and tolerability in children with systemic JIA
Monday, June 15, 2009 - 08:35
in Health & Medicine
Copenhagen, Denmark, Saturday 13 June 2009: Canakinumab (ACZ885), a new interleukin-1 (IL-1)-beta blocking monoclonal antibody, shows encouraging efficacy and is well tolerated in children with systemic juvenile idiopathic arthritis (sJIA)*, according to a new phase II study presented today at PReS 2009, a joint congress with the 2009 Congress of the European League Against Rheumatism (EULAR) i
Read the whole article on Science Blog
More from Science Blog
Related
- Canakinumab shows promising efficacy and tolerability in children with systemic JIAMon, 15 Jun 2009, 9:37:34 EDT
- Subclinical markers predict relapse in juvenile idiopathic arthritis post methotrexate withdrawalThu, 11 Jun 2009, 11:26:40 EDT
- Early treatment of systemic onset JIA with anakinra restores the IL-18 responseFri, 12 Jun 2009, 14:31:26 EDT
- Novel DNA vaccine leads to kidney damage prevention in systemic lupus erythematosus modelsThu, 11 Jun 2009, 10:58:51 EDT
- Diagnosis of arthritis 5 years earlier in childless women compared to those with childrenFri, 12 Jun 2009, 10:08:52 EDT